• 4,000 new contracted licenses in UK aged care market
• 9% quarter-on-quarter growth and $230,000 AUD ARR
• PainChek recognized as a priority solution in aged care

PainChek Ltd (ASX: PCK), developer of the world's first AI-powered pain assessment and monitoring application, has announced it has already achieved strong quarterly growth in the UK aged care market, with 4,000 new contracted licenses providing 9% quarter-on-quarter growth and an additional $230,000 AUD ARR once implemented. This growth reflects sustained demand for PainChek's clinically validated technology and builds on the positive outcomes data being observed across the UK. Facilities utilizing PainChek are increasingly reporting improved pain identification and management, supporting enhanced resident care and operational efficiencies. Importantly, PainChek is being recognized as a priority solution within aged care settings, with providers placing greater emphasis on effective pain management relative to other technology categories such as falls detection. This prioritization highlights the critical role pain assessment plays in improving quality of care and meeting regulatory expectations. PainChek's continued expansion in the UK is supported by a growing body of evidence demonstrating its impact across large-scale deployments, further reinforcing its position as a leading solution in the sector. Beyond the UK, the Company is also making positive progress in North America, where early commercial and strategic initiatives continue to advance. In addition, development and early deployment of PainChek's Infants product is progressing well, and the Company looks forward to providing updates on these initiatives in due course.

PainChek remains well positioned to capitalize on increasing global demand for digital health solutions in aged care settings, with major market opportunities in North America and other verticals still ahead.